Functional analysis of the NUP98-Topoisomerase 1 (NUP98-TOP1) fusion gene in the pathogenesis of leukemia.

摘要

Chromosomal rearrangements of the 11p15 locus have been identified in hematopoietic malignancies, resulting in translocations involving the N-terminal portion of the nucleoporin gene NUP98. Sixteen different fusion partner genes have been identified for NUP98 and over half of these are homeobox transcription factors. By contrast, the NUP98 fusion partner in t(11;20) is Topoisomerase I (TOP1), a catalytic enzyme recognized for its key role in relaxing supercoiled DNA. We now show that retrovirally engineered expression of NUP98-TOP1 in murine bone marrow (BM) confers a potent in vitro growth advantage and a block in differentiation in hematopoietic precursors. In a murine BM transplantation model, NUP98-TOP1 expression led to a lethal, transplantable acute myeloid leukemia (AML). To ascertain if NUP98-TOP1 acts through a novel pathway, a panel of NUP98-TOP1 mutants was engineered and tested for their sub-cellular localization and their growth promoting effects. Neither the NUP98-5' nor TOP1-3' portion of the fusion alone, nor a novel VP16-TOP1 fusion had any growth enhancing effects. Moreover, mutants lacking TOP1 domains known to be involved in DNA binding were also unable to transform myeloid progenitors. The TOP1-3' mutant exhibited ubiquitous GFP expression, while NUP98-5' and the DNA binding mutants localized to distinct nuclear bodies. In-vitro mutagenesis was employed to mutate the TOP1 active-site tyrosine (Y723F), a mutation known to abolish TOP1 catalytic activity. Similar to NUP98-TOP1, NT-Y723F exhibited a nuclear localization, had an in vitro growth advantage and induced a lethal, transplantable AML, suggesting that NUP98-TOP1 induces its leukemogenic effects independent of TOP1 catalytic, isomerase activity.; As observed with expression of other translocation fusion products, the long latency of disease onset suggests the acquisition of additional genetic mutations. Two approaches were used to identify potential NUP98-TOP1 collaborating genes. We chose the strong candidate gene Meis1, as it has previously been shown to accelerate leukemia induced by several NUP98-HOX fusions. However, no evidence for collaboration between Meis1 and NUP98-TOP1 was observed. Our second approach followed the serendipitous finding of NUP98-TOP1 retroviral integration into the ISCBP locus in a leukemic mouse. Strikingly, NUP98-TOP1 expression in ICSBP deficient bone marrow accelerated disease onset.; The results of this thesis add to the recognition of NUP98 fusion genes as an important class of leukemic fusion proteins. These studies further demonstrate the complexity of the molecular pathways involved in leukemogenesis.